A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment is a phase 3 interventional study registered as NCT07518147 by Sichuan Baili Pharmaceutical Co., Ltd., with 438 participants planned, started 2026-05-15 and due to reach its primary completion in 2029-12. Interventions recorded: BL-M05D1, Paclitaxel, Docetaxel and Irinotecan hydrochloride.